Resof L (Generic Harvoni) Birmingham — Hepatitis C Cure West Midlands UK 2026

 FAQ 1: What does SVR12 mean and does achieving it mean I am truly cured of Hepatitis C?

SVR12 (Sustained Virological Response at 12 weeks) means that Hepatitis C RNA is undetectable in the blood 12 weeks after completing the full DAA treatment course. This is considered a functional cure — long-term follow-up studies consistently show that over 99% of patients who achieve SVR12 remain HCV-free indefinitely. Unlike HIV, HCV does not integrate into human DNA in a way that allows it to reactivate. However, SVR12 does not provide immunity against future HCV infection — reinfection is possible if exposure occurs again, which is relevant for people who inject drugs or those with ongoing high-risk sexual behaviours. Birmingham hepatologists confirm SVR12 with a blood test at the 12-week post-treatment mark.

 FAQ 2: Will my liver damage reverse after being cured with Resof L?

Liver recovery after HCV cure depends on the degree of existing damage. Patients with mild fibrosis (F0-F2) typically see significant liver function improvement and near-complete recovery of liver architecture over 1-3 years post-cure. Those with moderate fibrosis (F3) also improve substantially. The crucial question is cirrhosis — patients with established cirrhosis (F4) do not reverse cirrhosis completely after cure, though liver inflammation resolves and further progression stops. Importantly, even cirrhotic patients significantly reduce their risk of liver failure and hepatocellular carcinoma after SVR12, though they still require surveillance with 6-monthly ultrasound because HCC risk persists (at reduced levels) for life in post-cirrhotic patients.

 FAQ 3: Can Resof L be taken during pregnancy?

Current guidance recommends avoiding DAA therapy including Ledipasvir+Sofosbuvir (Resof L) during pregnancy due to insufficient safety data in human pregnancies. Both components cross the placenta, and while animal studies have not shown teratogenicity at clinical doses, robust human data is lacking. The standard recommendation is to defer HCV treatment until after delivery and breastfeeding is complete. For women of reproductive age starting Resof L, effective contraception throughout treatment is advised. Birmingham hepatologists counsel all women of childbearing age on this before treatment, and pregnancy testing is done before initiating therapy.

 FAQ 4: How is Hepatitis C transmitted and can it spread through casual contact?

HCV is transmitted exclusively through blood-to-blood contact — it cannot spread through casual contact, sharing food, hugging, coughing, or sneezing. The primary transmission routes are: sharing needles, syringes, or other drug injection equipment (the most common route in the UK); unscreened blood transfusions or organ transplants (historical, before 1991 UK screening); sharing razors, toothbrushes, or nail clippers with an infected person; unsterile tattooing or body piercing; and sexual transmission (less efficient than HIV, but occurs particularly in MSM with high-risk practices). Healthcare workers can be exposed through needlestick injuries. This blood-only transmission means Birmingham families living with an HCV-positive member face essentially no risk from everyday household contact.

 FAQ 5: Does Resof L work for all Hepatitis C genotypes or only some?

Resof L (Ledipasvir+Sofosbuvir) has strongest evidence for Genotypes 1, 4, 5, and 6. Genotype 1 — the most common in the UK, USA, and Europe — achieves SVR12 rates above 95%. For Genotypes 2 and 3 (more common in South Asia and some African populations represented in Birmingham's diverse community), alternative regimens incorporating Velpatasvir rather than Ledipasvir are preferred — specifically Sofosbuvir+Velpatasvir (Epclusa). Before starting Resof L, Birmingham hepatologists always confirm the patient's HCV genotype through a simple blood test to ensure the most appropriate regimen is selected.